Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CEA cell adhesion molecule pseudogene 2 (CEACAMP2) is a member of the carcinoembryonic antigen (CEA)-related cell adhesion molecule (CEACAM) gene family, but it is classified as a **pseudogene**, meaning it does not encode a functional protein. Pseudogenes arise from gene duplication or retrotransposition events and usually bear high sequence similarity to protein-coding genes but are rendered non-functional by mutations, deletions, or lack of regulatory elements. As a pseudogene, CEACAMP2 is not considered a therapeutic target, does not have established biological functions or disease relevance, and has no known interactions with drugs or roles as a biomarker. There is nothing to suggest from the biomedical literature that CEACAMP2 is involved in any disease mechanisms or therapeutic pathways relevant to the functional CEACAM proteins such as CEACAM1, CEACAM5, or CEACAM6. Its inclusion as a target is likely due to an error, confusion with related functional proteins, or automated extraction from gene lists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CEA cell adhesion molecule pseudogene 2 (CEACAMP2).